Trends in the care of diabetic macular edema: Analysis of a national cohort

PLoS ONE

Volumn 11, Issue 2, 2016, Pages

  VanderBeek, Brian L ^a,b   Shah, Neepa ^a   Parikh, Purak C ^a   Ma, Liyuan ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; STEROID; VASCULOTROPIN INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DIABETIC MACULAR EDEMA; FEMALE; HEALTH INSURANCE; HUMAN; INCIDENCE; LOW LEVEL LASER THERAPY; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PATIENT MONITORING; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREND STUDY; UNITED STATES; ANTAGONISTS AND INHIBITORS; DIABETES COMPLICATIONS; FOLLOW UP; IMMUNOLOGY; MACULAR EDEMA; MIDDLE AGED;

BEVACIZUMAB; COHORT STUDIES; DIABETES COMPLICATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LASER THERAPY; MACULAR EDEMA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; UNITED STATES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84977664870     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0149450     Document Type: Article

References (17)

1. Varma R, Bressler NM, Doan QV, Gleeson M, Danese M, Bower JK, et al. (2014) Prevalence of and Risk Factors for Diabetic Macular Edema in the United States. JAMA Ophthalmol.
2. Do DV, Nguyen QD, Khwaja AA, Channa R, Sepah YJ, Sophie R, et al. (2012) Ranibizumab for Edema of the Macula in Diabetes Study: 3-Year Outcomes and the Need for Prolonged Frequent Treatment. Arch Ophthalmol: 1-7.
3. Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al. (2012) Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 119: 789-801. doi: 10.1016/j.ophtha.2011.12.039 PMID: 22330964
4. Mitchell P, Annemans L, Gallagher M, Hasan R, Thomas S, Gairy K, et al. (2012) Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial. Br J Ophthalmol 96: 688-693. doi: 10.1136/bjophthalmol-2011-300726 PMID: 22399690
5. Elman MJ, Qin H, Aiello LP, Beck RW, Bressler NM, Ferris FL 3rd, et al. (2012) Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology 119: 2312-2318. doi: 10.1016/j.ophtha.2012.08.022 PMID: 22999634
6. Rajendram R, Fraser-Bell S, Kaines A, Michaelides M, Hamilton RD, Esposti SD, et al. (2012) A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol 130: 972-979. PMID: 22491395
7. Do DV, Nguyen QD, Boyer D, Schmidt-Erfurth U, Brown DM, Vitti R, et al. (2012) One-year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology 119: 1658-1665. doi: 10.1016/j.ophtha.2012.02.010 PMID: 22537617
8. Curtis LH, Hammill BG, Qualls LG, DiMartino LD, Wang F, Schulman KA, et al. (2012) Treatment patterns for neovascular age-related macular degeneration: analysis of 284 380 medicare beneficiaries. Am J Ophthalmol 153: 1116-1124 e1111. doi: 10.1016/j.ajo.2011.11.032 PMID: 22321802
9. Lad EM, Hammill BG, Qualls LG, Wang F, Cousins SW, Curtis LH (2014) Anti-VEGF Treatment Patterns for Neovascular Age-Related Macular Degeneration Among Medicare Beneficiaries. Am J Ophthalmol.
10. Holekamp NM, Liu Y, Yeh WS, Chia Y, Kiss S, Almony A, et al. (2014) Clinical utilization of anti-VEGF agents and disease monitoring in neovascular age-related macular degeneration. Am J Ophthalmol 157: 825-833 e821. doi: 10.1016/j.ajo.2013.12.018 PMID: 24388973
11. Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, et al. (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119: 1388-1398. doi: 10.1016/j.ophtha.2012.03.053 PMID: 22555112
12. Kiss S, Liu Y, Brown J, Holekamp NM, Almony A, Campbell J, et al. (2014) Clinical utilization of antivascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema. Clin Ophthalmol 8: 1611-1621. doi: 10.2147/OPTH.S60893 PMID: 25210429
13. Jusufbegovic D, Mugavin MO, Schaal S (2015) EVOLUTION OF CONTROLLING DIABETIC RETINOPATHY: Changing Trends in the Management of Diabetic Macular Edema at a Single Institution Over the Past Decade. Retina.
14. Schneider EW, Mruthyunjaya P, Talwar N, Harris Nwanyanwu K, Nan B, Stein JD (2014) Reduced fluorescein angiography and fundus photography use in the management of neovascular macular degeneration and macular edema during the past decade. Invest Ophthalmol Vis Sci 55: 542-549. doi: 10.1167/iovs.13-13034 PMID: 24346174
15. Bearelly S, Mruthyunjaya P, Tzeng JP, Suner IJ, Shea AM, Lee JT, et al. (2008) Identification of patients with diabetic macular edema from claims data: a validation study. Arch Ophthalmol 126: 986-989. doi: 10.1001/archopht.126.7.986 PMID: 18625948
16. Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, et al. (2010) Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 117: 1064-1077 e1035. doi: 10.1016/j.ophtha.2010.02.031 PMID: 20427088
17. The Diabetic Retinopathy Clinical Research Network. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. The New England journal of medicine. Feb 18 2015.